Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...
The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.
Novo Nordisk has said will be gaining exclusive worldwide rights to United Laboratories International’s investigational ...
a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases. Under the license agreement ...
Live Mint on MSN13d
Mounjaro hits shelves in India: How Eli Lilly’s weight loss drug compares with Ozempic — price, side effects and moreEli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
The issuer is solely responsible for the content of this announcement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback